D

Duopharma Biotech Bhd
KLSE:DPHARMA

Watchlist Manager
Duopharma Biotech Bhd
KLSE:DPHARMA
Watchlist
Price: 1.2 MYR Market Closed
Market Cap: 1.2B MYR
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Average
N/A
Revenue
Forecast
N/A
Operating Income
Forecast
N/A
Net Income
Forecast
N/A

Wall Street
Price Targets

DPHARMA Price Targets Summary
Duopharma Biotech Bhd

Wall Street analysts forecast DPHARMA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for DPHARMA is 1.53 MYR with a low forecast of 1.4 MYR and a high forecast of 1.7 MYR.

DPHARMA Lowest Forecast
Wall Street Target
1.4 MYR
17% Upside
DPHARMA Average Forecast
Wall Street Target
1.53 MYR
28% Upside
DPHARMA Highest Forecast
Wall Street Target
1.7 MYR
42% Upside
Lowest
Price Target
1.4 MYR
17% Upside
Average
Price Target
1.53 MYR
28% Upside
Highest
Price Target
1.7 MYR
42% Upside
Duopharma Biotech Bhd Competitors:
Price Targets
KLBF
Kalbe Farma Tbk PT
55% Upside
MARKSANS
Marksans Pharma Ltd
38% Upside
4502
Takeda Pharmaceutical Co Ltd
10% Upside
A
AHEALTH
Apex Healthcare Bhd
35% Upside
KLBF
Kalbe Farma Tbk PT
55% Upside
MARKSANS
Marksans Pharma Ltd
38% Upside
4502
Takeda Pharmaceutical Co Ltd
10% Upside
A
AHEALTH
Apex Healthcare Bhd
35% Upside
ERIS
Eris Lifesciences Ltd
10% Upside
C
CONCORDBIO
Concord Biotech Ltd
14% Upside

Revenue
Forecast

Revenue Estimate
Duopharma Biotech Bhd

For the last 8 years the compound annual growth rate for Duopharma Biotech Bhd's revenue is 13%. The projected CAGR for the next 4 years is 10%.

13%
Past Growth
10%
Estimated Growth
Estimates Accuracy
-4%
Average Miss
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Duopharma Biotech Bhd

For the last 8 years the compound annual growth rate for Duopharma Biotech Bhd's operating income is 6%. The projected CAGR for the next 4 years is 17%.

6%
Past Growth
17%
Estimated Growth
Estimates Accuracy
-11%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Duopharma Biotech Bhd

For the last 8 years the compound annual growth rate for Duopharma Biotech Bhd's net income is 5%. The projected CAGR for the next 3 years is 22%.

5%
Past Growth
22%
Estimated Growth
Estimates Accuracy
-9%
Average Miss
What are analyst estimates?

See Also

Summary
DPHARMA intrinsic value, competitors valuation, and company profile.
DCF Valuation
DPHARMA stock valuation using Discount Cash Flow valuation method.
Relative Valuation
DPHARMA stock valuation using valuation multiples.
Wall Street Estimates
DPHARMA price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
DPHARMA stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is DPHARMA's stock price target?
Price Target
1.53 MYR

According to Wall Street analysts, the average 1-year price target for DPHARMA is 1.53 MYR with a low forecast of 1.4 MYR and a high forecast of 1.7 MYR.

What is Duopharma Biotech Bhd's Revenue forecast?
Projected CAGR
10%

For the last 8 years the compound annual growth rate for Duopharma Biotech Bhd's revenue is 13%. The projected CAGR for the next 4 years is 10%.

What is Duopharma Biotech Bhd's Operating Income forecast?
Projected CAGR
17%

For the last 8 years the compound annual growth rate for Duopharma Biotech Bhd's operating income is 6%. The projected CAGR for the next 4 years is 17%.

What is Duopharma Biotech Bhd's Net Income forecast?
Projected CAGR
22%

For the last 8 years the compound annual growth rate for Duopharma Biotech Bhd's net income is 5%. The projected CAGR for the next 3 years is 22%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 240,500+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.